The last time I spoke about Zenas BioPharma, Inc. (ZBIO), it was with a Seeking Alpha article entitled "Zenas: Maintaining ...

Q1 2026 earnings call highlights: 4.4% same-property NOI, guidance intact, $600M pipeline, balance sheet strength—read now.

"We are still targeting annual equity issuances of $500 million to $600 million in 2026 through 2028 with similar levels through 2030" and "we target an FFO to debt ratio of approximately 15%" (Vice ...

"Total revenue in the first quarter was $122 million" (Chief Financial Officer Guy Zeltser), and "Q1 net income came in at $7 million or $0.27 per diluted share" alongside "Q1 adjusted net income" of ...

Nuvalent is positioned as a high-quality late-stage biotech with two near-commercial precision oncology assets. Read more on ...

Q1 2026 earnings call: revenue +12% to $3.7B, Industrial separation plan (sale/spin) in 12–18 months, outlook & risks—read now.

Ditch the outdated 60/40 mix: see why a simple S&P 500 + T-bills 50/50 beats “moderate” funds, and learn selective ETF picks ...

Meta Platforms delivered robust Q1 results, with 33% YoY revenue growth and a 62% EPS beat, yet shares fell on increased ...

Advanced Micro Devices, Inc.’s 50x forward earnings multiple reflects expected future growth. Click here to read an analysis ...

Q1 2026 Earnings Call April 30, 2026 8:00 AM EDTCompany ParticipantsCharles Sebaski - Head of Investor RelationsRichard ...

Q1 2026 Earnings Call April 30, 2026 8:00 AM EDTCompany ParticipantsLeigh Mann - Vice President of Investor RelationsE.

Cullinan Therapeutics, Inc. has a cash-rich balance sheet and no financial debt while trading at a reasonable valuation. Read ...